Novartis Ag (NVS) Cash from Operations (2009 - 2026)
Novartis Ag (NVS) posted Cash from Operations of 5882000000.0 for Q2 2026, down 11.73% sequentially from 6664000000.0 in Q2 2025, and down 11.73% YoY from 6664000000.0 in Q2 2025.
Novartis Ag (NVS) Cash from Operations (2009 - 2026) Analysis & Trends
Novartis Ag has reported Cash from Operations for 14 years, with the latest figure at 5882000000.0 in Q2 2026.
- Quarterly Cash from Operations fell 11.73% year-over-year to 5882000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 24561000000.0 (up 10.36% YoY) and the FY2025 annual result came in at 19144000000.0, up 8.66% from the prior year.
- Cash from Operations retreated to 5882000000.0 in Q2 2026 per NVS's latest filing, from 6664000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 7140000000.0 in Q4 2024 and troughed at 3576000000.0 in Q2 2023.
- A 5-year average of 5315333333.33 and a median of 5378500000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations soared 36.7% in 2025, then slipped 11.73% in 2026.
- Over 5 years, Cash from Operations stood at 3755000000.0 in 2022, then fell by 4.77% to 3576000000.0 in 2023, then jumped by 99.66% to 7140000000.0 in 2024, then slipped by 6.67% to 6664000000.0 in 2025, then slipped by 11.73% to 5882000000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 5882000000.0, 6664000000.0, and 7140000000.0 for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.88 Bn |
| Jun 30, 2026 | 5.88 Bn |
| Jun 30, 2025 | 6.66 Bn |
| Jun 30, 2025 | 6.66 Bn |
| Dec 31, 2024 | 7.14 Bn |
| Dec 31, 2024 | 7.14 Bn |
| Jun 30, 2024 | 4.88 Bn |
| Jun 30, 2024 | 4.88 Bn |
| Jun 30, 2023 | 3.58 Bn |
| Jun 30, 2023 | 3.58 Bn |
| Jun 30, 2022 | 3.76 Bn |
| Jun 30, 2022 | 3.76 Bn |
| Jun 30, 2021 | 4.16 Bn |
| Jun 30, 2021 | 4.16 Bn |
| Jun 30, 2020 | 3.96 Bn |
| Jun 30, 2020 | 3.96 Bn |
| Jun 30, 2019 | 3.11 Bn |
| Jun 30, 2019 | 3.11 Bn |
| Jun 30, 2018 | 3.94 Bn |
| Jun 30, 2018 | 3.94 Bn |